Bleeding in patients with hemophilia who have inhibitors: Modeling US medical system utilization and cost avoidance between recombinant factor VIIa products with different clinical dosing requirements.

Alexander, W Allan; Jensen, Ivar; Hathway, Joanne; Srivastava, Krutika; Cyr, Philip; Sidonio, Robert F; Batt, Katharine

Alexander, W Allan; Jensen, Ivar; Hathway, Joanne; Srivastava, Krutika; Cyr, Philip; Sidonio, Robert F; Batt, Katharine.

Affiliation

Alexander WA; Independent Consultant, Athens.
Jensen I; PRECISIONheor, Boston, Hathway, MA.
Hathway J; PRECISIONheor, Boston, Hathway, MA.
Srivastava K; PRECISIONheor, Boston, Hathway, MA.
Cyr P; PRECISIONheor, Boston, Hathway, MA.
Sidonio RF; Department of Pediatrics - Hematology, School of Medicine, Emory University, Atlanta, GA.
Batt K; Independent Consultant, Winston-Salem, NC.

J Manag Care Spec Pharm ; 28(5): 518-527, 2022 May.

Article in En | MEDLINE | ID: mdl-35343812

Subject(s)

Biological Products; Hemophilia A; Biological Products/therapeutic use; Factor VIIa/adverse effects; Hemophilia A/drug therapy; Hemorrhage; Humans; Male; Recombinant Proteins; United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Biological Products / Hemophilia A Type of study: Health_economic_evaluation / Prognostic_studies Limits: Humans / Male Country/Region as subject: America do norte Language: En Journal: J Manag Care Spec Pharm Year: 2022 Type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google